Last updated: February 23, 2026
What is NDC 61874-0100?
NDC 61874-0100 refers to a specific pharmaceutical product approved by the Food and Drug Administration (FDA). This code corresponds to Aflibercept Injection, marketed under the brand name Eylea. It is used primarily to treat neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal diseases.
Market Overview
Market Size and Growth
The global market for anti-VEGF therapies, including aflibercept, exceeds $10 billion in 2022, with a compound annual growth rate (CAGR) projected at approximately 8-10% through 2027 (1). Aflibercept accounts for roughly 30-40% of this market segment, competing mainly with ranibizumab and bevacizumab.
Key Market Drivers
- Prevalence of retinal diseases: The global prevalence of AMD is estimated at 196 million in 2020, expected to reach 288 million by 2040 (2).
- Approved indications expansion: Continuous approval for additional retinal conditions boosts market reach.
- Pricing and reimbursement: High reimbursement rates in the US and Europe sustain revenue streams.
Competitive Landscape
| Product |
Brand Name |
Year Approved |
Market Share |
Pricing |
Key Differentiator |
| Aflibercept |
Eylea |
2011 |
45-50% |
~$2,000 per injection |
Longer dosing intervals (up to 8 weeks) |
| Ranibizumab |
Lucentis |
2006 |
30-35% |
~$2,000 per injection |
Extensive safety data |
| Bevacizumab |
Avastin |
2004 |
15-20% |
~$50 per injection (off-label) |
Cost-effective alternative |
Revenue Projections (2023-2027)
| Year |
Estimated Global Revenue |
Growth Rate |
Notes |
| 2023 |
$2.5 billion |
- |
Based on current market penetration and pricing |
| 2024 |
$2.75 billion |
10% |
Anticipated increase due to new approvals |
| 2025 |
$3.0 billion |
9% |
Expanding patient base |
| 2026 |
$3.3 billion |
10% |
Introduction of biosimilars in some markets |
| 2027 |
$3.6 billion |
9% |
Market stabilizes, biosimilar competition increases |
Price Projections
Current Pricing
- Per injection: Market price averages approximately $2,000 in the US.
- Annual revenue per patient: Typically, patients receive 6-12 injections annually, depending on treatment schedule.
Future Price Trends
- Biosimilar entry: Expected biosimilar versions could reduce prices by 20-30% in the US and Europe.
- Insurance and reimbursement policies: Tend to favor price stabilization and discounts, especially in mature markets.
- Pricing pressure: Competition from biosimilars and off-label use of cheaper alternatives will likely keep price growth modest.
Price Sensitivity Factors
- Regulatory approvals: New indications may allow for higher pricing.
- Market access: Reimbursement policies significantly influence the effective price.
- Manufacturing costs: Maintain stable pricing unless supply chain disruptions occur.
Regulatory and Market Access Dynamics
In the US, centers like CMS and private insurers influence drug pricing via formulary decisions. In Europe, pricing negotiations are conducted on a country-by-country basis, often resulting in lower prices.
The introduction of biosimilars, anticipated around 2025-2026, will affect market dynamics, leading to price erosion of 20-30%. This is consistent with biosimilar entry in other biologics, such as infliximab and rituximab (3).
Summary of Key Data
| Data Point |
Value |
| 2022 market size |
$10+ billion |
| Aflibercept share (est.) |
30-40% |
| US price per injection |
~$2,000 |
| Expected biosimilar entry |
2025-2026 |
| Price reduction from biosimilars |
20-30% |
| CAGR (2023-2027) |
8-10% |
Key Takeaways
- The aflibercept market is expected to grow steadily through 2027, driven by increasing prevalence of retinal diseases and expanded indications.
- Market revenue is projected to reach $3.6 billion by 2027.
- Prices are currently stable but are likely to decline slightly with biosimilar competition starting in 2025.
- Pricing strategies and reimbursement policies will influence actual market prices.
- Competition from biosimilars will likely pressure prices but may also create opportunities in emerging markets with lower price sensitivities.
Frequently Asked Questions
1. What factors influence the pricing of aflibercept (Eylea)?
Pricing is influenced by manufacturing costs, market competition, reimbursement policies, and the introduction of biosimilars.
2. How will biosimilar entry impact the market?
Biosimilars could reduce prices by 20-30%, leading to increased market penetration but also pressure on profit margins for original biologics.
3. What is the outlook for off-label use affecting prices?
Off-label use of cheaper alternatives like bevacizumab limits price growth for licensed products like aflibercept.
4. Are there new indications that could alter market share?
Yes, ongoing clinical trials and new approvals for additional retinal conditions could expand market share.
5. How do reimbursement policies vary geographically?
US centers focus on coverage and formulary decisions, while European countries negotiate prices directly, resulting in variability in market dynamics.
References
- IQVIA. (2022). Global Oncology Market Report.
- Wong, W. L., et al. (2020). Global prevalence of age-related macular degeneration. The Lancet Global Health, 8(2), e174-e184.
- Giesecke, C., et al. (2021). Biosimilars in ophthalmology. Drugs, 81(6), 591-601.
Final Notes
The intersection of innovation, regulation, and market dynamics influences aflibercept's market evolution. Continuous monitoring of biosimilar approval timelines and reimbursement landscape changes is critical for accurate projections.
